Navigation Links
Reportlinker Adds Future Directions in Regenerative Medicine
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future Directions in Regenerative Medicine

http://www.reportlinker.com/p0511976/Future-Directions-in-Regenerative-Medicine.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a "tipping point", after which no medical industry players will want to be left behind.

This report covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, and medical devices. Each company profiled has at least one project in preclinical or Phase I study. Many also have later stage or launched products, which are covered briefly to illustrate the potential of the next generation of candidates.

Scope of this research

• Understand the concepts behind regenerative medicine, its potential applications, and advantages over traditional medicine.

• Compare the opportunities and challenges presented by the different therapeutic modalities.

• Understand the hurdles that must be overcome by regenerative medicine candidates before they can successfully enter the market.

• Identify emerging technologies that will shape the regenerative medicine industry in the coming years.

• Identify companies that may be competitors for a market, or alternatively potential partners or investment opportunities.

Research and analysis highlights

The first regenerative cell therapies to generate significant market value (within the next five years) will be based on allogeneic adult cells, and will target tissues that are naturally sheltered from patients' immune systems.

Autologous cells are not rejected by the patient's immune system, so are potentially safer than allogeneic cells and more suitable for permanent tissue replacement. "High tech" therapies based on reprogrammed autologous cells (e.g. induced pluripotent stem cells) may still be 20 years from market.

Tissue engineering still faces technical hurdles, including vascularization of grafted tissue and safe breakdown of scaffold materials. Research and regulatory efforts must be coordinated internationally to develop a stronger "evidence base" for regenerative medicine that is accessible and acceptable to all stakeholders.

Key reasons to purchase this research

• What is regenerative medicine and why are so many companies and investors excited about it?

• Which companies are currently developing new regenerative treatments and what approaches are they pursuing?

• What partnerships have been formed to develop new therapies, and where are the opportunities for further deals?

• What will the next generation of regenerative medicine candidates look like, and which indications will they treat?

• What hurdles do these candidates face en route to the marketplace?

TABLE OF CONTENTS

About the author 2

Disclaimer 2

Executive Summary 12

An introduction to regenerative medicine 12

Allogeneic regenerative cell therapies 12

Autologous regenerative cell therapies 13

Tissue engineering 14

Regenerative drug molecules 14

Regenerative devices and implants 15

The future of regenerative medicine 15

Chapter 1 An introduction to regenerative medicine 17

Summary 17

Introduction 17

Cell-based therapies 18

Tissue engineering 19

Acellular therapies 20

Chapter 2 Allogeneic regenerative cell therapies 21

Summary 21

Introduction 21

Case studies 23

Advanced Cell Technology 24

Altrika 25

Athersys 26

BetaLogics 29

BioTime – embryonic progenitor cells 29

California Stem Cell 31

Cardio3 Biosciences 32

Celgene Cellular Therapeutics 33

Effector Cell Institute 33

Gamida Cell 34

Genzyme and Osiris Therapeutics 35

Geron 36

International Stem Cell 39

ISTO Technologies 40

MediStem – universal donor cells and cord blood transplants 41

Mesoblast – mesenchymal precursor cells 43

NeuralStem – fetal neural stem cells 45

Pfizer 46

Pluristem Therapeutics 47

Promethera Biosciences 49

Proteonomix 50

ReNeuron Group 50

Saneron CCEL Therapeutics. 51

Stematix 52

StemCells 52

Stemedica Cell Technologies 54

Stempeutics Research 55

TiGenix – allogeneic MSCs 55

TissueGene 56

Summary of allogeneic cell therapies in development 57

Discussion 63

Technical issues 63

Regulatory issues 66

Logistical issues 66

Conclusions 67

Chapter 3 Autologous regenerative cell therapies 69

Summary 69

Introduction 69

Case studies 71

Aastrom Biosciences 72

Aldagen 72

American Medical Systems Holdings 75

Amorcyte 75

Azellon 75

Bioheart 76

BioTime – induced pluripotent stem cells 77

BrainStorm Cell Therapeutics 79

Cytori Therapeutics 80

Ectycell 81

GeneGrafts 82

GlaxoSmithKline 83

Intercytex 84

LoneStar Heart – regenerative cell induction 86

MedCell Bioscience 86

MediStem – Tolerostem 86

MultiGene Vascular Systems 87

Novartis – monocyte derived islet cells 88

StemSave 88

TCA Cellular Therapy 89

Tissue Genesis Inc. 89

TriStem 90

Summary of autologous cell therapies in development 91

Discussion 96

Technical issues 96

Regulatory issues 98

Logistical issues 99

Conclusions 100

Chapter 4 Tissue engineering 102

Summary 102

Introduction 102

Case studies 103

Advanced BioHealing 104

CellSeed 104

Cerco Medical 105

Cytograft Tissue Engineering 106

Japan Tissue Engineering Company 107

Living Cell Technologies 108

Lonza Group and Regenicin 109

Organogenesis 109

Organovo 110

Pervasis Therapeutics 112

Tengion 114

ViaCyte 115

Summary of tissue engineering treatments in development 116

Discussion 119

Technical issues 119

Regulatory issues 120

Logistical issues 120

Conclusions 121

Chapter 5 Regenerative drug molecules 122

Summary 122

Introduction 122

Case studies 124

Angion Biomedica 124

Cardio3 Biosciences 124

DeveloGen 125

DiaMedica 125

ImmuneRegen BioSciences 126

Epistem 127

Fate Therapeutics 128

Juventas Therapeutics 128

LoneStar Heart – cardiac stem cell modulators 129

Mesoblast – SDF-1 130

NeuralStem – NSI-189 130

NeuroNova 131

Novartis – TherAtoh 131

Olympus Biotech 132

Sanofi-Aventis 133

Stryker 133

Stem Cell Therapeutics 134

Tissue Repair Company 134

Trillium Therapeutics 137

Summary of regenerative drug molecules in development 137

Discussion 140

Technical issues 140

Regulatory issues 141

Logistical issues 141

Conclusions 141

Chapter 6 Regenerative devices and implants 143

Summary 143

Introduction 143

Case studies 144

Alacer Biomedical 144

Kensey Nash 145

Mesynthes 146

Nanotope 146

Neopec 148

Neotherix 149

RepRegen 150

TheraGlass 151

TiGenix – biomaterials 152

Tissue Regenix Group 152

Summary of regenerative devices in development 153

Discussion 155

Technical issues 155

Regulatory issues 156

Logistical issues 156

Conclusions 156

Chapter 7 The future of regenerative medicine 158

Summary 158

Introduction 158

Investment in regenerative medicine 158

Reimbursement 160

Hope versus hype 161

Appendix 163

Scope 163

Methodology 163

Primary research 163

Secondary research 164

Abbreviations 164

References 172

Company websites 172

Journal and magazine articles 178

Patent documents 181

Table of figures

Figure 1: Allogeneic regenerative cell therapy 23

Figure 2: Autologous regenerative cell therapy 71

Figure 3: Tissue engineering 103

Figure 4: NovoGen bioprinting 111

Figure 5: Regenerative drug therapy 123

Figure 6: Regenerative medical device therapy 144

Table of tables

Table 1: Allogeneic regenerative cell therapies under development (part 1) 57

Table 2: Allogeneic regenerative cell therapies under development (part 2) 58

Table 3: Allogeneic regenerative cell therapies under development (part 3) 59

Table 4: Allogeneic regenerative cell therapies under development (part 4) 60

Table 5: Allogeneic regenerative cell therapies under development (part 5) 61

Table 6: Allogeneic regenerative cell therapies under development (part 6) 62

Table 7: Autologous regenerative cell therapies under development (part 1) 92

Table 8: Autologous regenerative cell therapies under development (part 2) 93

Table 9: Autologous regenerative cell therapies under development (part 3) 94

Table 10: Autologous regenerative cell therapies under development (part 4) 95

Table 11: Tissue engineering treatments under development (part 1) 117

Table 12: Tissue engineering treatments under development (part 2) 118

Table 13: Regenerative drug molecules under development (part 1) 138

Table 14: Regenerative drug molecules under development (part 2) 139

Table 15: Regenerative drug molecules under development (part 3) 140

Table 16: Regenerative devices under development (part 1) 154

Table 17: Regenerative devices under development (part 2) 155

To order this report:

Biological Therapy Industry: Future Directions in Regenerative Medicine

Biological Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
2. Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries
3. Reportlinker Adds Analytical Tool - Lymphoma
4. Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope
5. Reportlinker Adds Industrial Biotechnology China News 1104
6. Reportlinker Adds Healthcare Information Technology
7. Reportlinker Adds Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
8. Reportlinker Adds Global Biomaterial Market (2010 - 2015)
9. Reportlinker Adds Genetics Reports Bundle
10. Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Biomarkers: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):